Novocure (NSDQ:NVCR) shares took a dive today on second-quarter results that came up short of the consensus forecast. NVCR shares were down -11.7% at $160.67 in mid-afternoon trading today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — was up 0.9% on the day. The St. Helier, N.J.-based […]
NovoCure
Novocure’s Optune wins innovative medical device designation from China
NovoCure (NSDQ:NVCR) said today that it was granted Innovative Medical Device Designation in China for its Optune tumor treating system. The Optune system uses electric fields that are tuned in to specific frequencies to disrupt cancer cell division, according to the company. The technology inhibits tumor growth and causes cancer cells to die. Zai Lab has […]
FDA approves Novocure’s NovoTTF-100LTM plus chemo for mesothelioma
NovoCure (NSDQ:NVCR) announced that it has received FDA approval for its NovoTTF-100L system with chemotherapy for treating a type of mesothelioma. NovoTTF-100L is a non-invasive, antimitotic cancer treatment designed to deliver electric fields at special frequencies to disrupt solid tumor cancer cell division. Approved under a humanitarian device exemption, NovoTTF-100L and pemetrexed plus platinum-based chemotherapyis indicated […]
Novocure launches pivotal ovarian cancer trial
Novocure (NSDQ:NVCR) said today that it kicked off a Phase 3 pivotal trial testing its Tumor Treating Fields therapy combined with paclitaxel in people with recurrent, platinum-resistant ovarian cancer. The 540-patient trial has a primary endpoint of overall survival, with secondary endpoints that include progression-free survival, objective response rate, severity and frequency of adverse events and […]
Novocure shares dip on Q4, 2018 earnings miss
Shares in Novocure (NSDQ:NVCR) fell slightly today after the medical device maker missed expectations on Wall Street with its fourth quarter and full year 2018 earnings release. The St. Helier, Jersey-based company posted losses of $15.6 million, or 17¢ per share, on sales of $69.7 million for the three months ended December 31, seeing losses grow […]
Novocure touts analysis of pivotal glioblastoma trial results
Novocure (NSDQ:NVCR) today touted the results of a retrospective sub-group analysis of its EF-14 Phase III pivotal trial in patients with newly diagnosed glioblastoma. The analysis, which was published in the Journal of Neuro-Oncology, demonstrated that more time on Novocure’s Optune device predicted increased survival in people who received Optune plus temozolomide compared to those who received […]
NovoCure slides on Q3 sales miss
NovoCure (NSDQ:NVCR) shares took a hit today, despite lower-than-forecast losses, after the company reported financial results that missed expectations for third-quarter sales. NVCR shares were down-12.7% to $36.23 today in late-morning trading on the news. Get the full story on our sister site, MassDevice.com.
Novocure touts Phase II pancreatic cancer pilot study
Novocure (NSDQ:NVCR) today touted the results of a Phase II pilot trial designed to test the feasibility, safety and efficacy of its Tumor Treating Fields therapy in patients with unresectable, advanced pancreatic cancer. The St. Helier, N.J.-based company’s Optune device uses electric fields, called Tumor Treating Fields, to disrupt cell division, inhibit tumor growth and trigger […]
Novocure inks Chinese collaborative deal with Zai Lab
Novocure (NSDQ:NVCR) said today it inked a $15 million licensing agreement with Shanghai-based biopharma company Zai Lab to offer its Optune technology on the Chinese market and accelerate clinical trial enrollment in the region. The Optune device delivers low-intensity, intermediate frequency, alternating electric fields, called “Tumor Treating Fields,” to inhibit cancer cell replication. Through the agreement, Novocure granted […]
Novocure touts combined TTF, chemotherapy mesothelioma study data
Novocure (NSDQ:NVCR) today released results from the Stellar phase 2 registration trial exploring the use of its Tumor Treating Fields and standard of care chemotherapy to chemotherapy alone in treating mesothelioma, touting a significant extension in median overall survival. Patients with malignant pleural mesothelioma who received TTF treatment alongside pemetrexed and cisplatin or carboplatin experienced a […]
